InvestorBrandNetwork (IBN) Content Platform

Quant Strats USA 2025, held on March 11 at Quorum by Convene in New York, brought together over 380 professionals in quantitative finance, with 70% of attendees representing the Buy-Side, including hedge funds, asset managers, and investment banks. The event reaffirmed its role as a premier forum for exploring advancements in artificial intelligence (“AI”), machine learning (“ML”), and large language models (“LLMs”) within finance, offering attendees unparalleled access to industry-leading insights and networking opportunities.

The conference featured over 50 expert speakers who examined how AI and ML are no longer just theoretical innovations but essential tools shaping investment strategies, risk management, and trade execution. AI & ML in Asset Management addressed how firms are integrating advanced algorithms into portfolio construction, risk assessment, and trade execution to drive efficiency and improve returns. The Future of Large Language Models (“LLMs”) in Quant Finance explored how LLMs are being leveraged for predictive modeling, sentiment analysis, and automating complex financial decision-making. The discussion underscored the increasing reliance on AI-driven insights to navigate evolving market conditions and improve performance.

A central theme throughout the event was the growing synergy between quantitative and fundamental investment strategies. Blending Quant & Fundamental Strategies featured leading portfolio managers and quant strategists who discussed the complexities of combining data-driven models with traditional financial analysis, highlighting the benefits and challenges of hybrid approaches. Meanwhile, Alternative Data & Alpha Generation explored how non-traditional data sources, ranging from satellite imagery to consumer transaction data, are unlocking new opportunities for alpha generation, providing firms with an edge in systematic trading.

With the rapid evolution of electronic trading, High-Frequency Trading & Execution Algorithms took a deep dive into the latest advancements in trade execution, latency reduction, and market-making strategies. The session provided a comprehensive look at how firms are optimizing execution in an increasingly automated environment. Meanwhile, Risk Management in a Volatile Market tackled the challenges of adapting quant strategies to turbulent market conditions, emphasizing the importance of robust risk frameworks in mitigating potential losses and ensuring long-term portfolio stability.

Beyond the content-rich sessions, Quant Strats USA 2025 offered extensive networking opportunities, allowing attendees to connect with top-tier data scientists, quantitative analysts, institutional investors, and technology providers. The event’s focus on practitioner-led discussions ensured that participants left with actionable takeaways, equipping them with cutting-edge tools and strategies to navigate the evolving landscape of quantitative finance.

The discussions and insights from Quant Strats USA 2025 will continue later this year at Quant Strats Europe, offering another opportunity for professionals to engage with global leaders in the field. As AI and ML continue to drive transformation in quantitative finance, staying ahead of these developments is crucial. Attendees of Quant Strats Europe can expect in-depth discussions on the latest trends, hands-on workshops, and expanded networking opportunities designed to help firms remain competitive in an increasingly data-driven industry. For more details and to secure participation, visit Quant Strats Europe.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

KRTL HOLDING Group (OTC: KRTL), a diversified holding company focused on biotechnology innovation, global API sourcing, and cross-border distribution solutions, has commenced trading on Upstream under ticker symbol KRTL. “We are thrilled to dual list on Upstream’s next-generation marketplace. This milestone supports our mission to drive innovation and expand across the global environment by securing FDA-compliant supply chains and ensuring the availability of critical healthcare inputs in the U.S. market under the highest regulatory standards,” said Cesar Herrera, CEO of KRTL.

“By up-listing on Upstream and in light of the international deals ahead, we’re creating new opportunities for our partners, international consultants, and global investors to access a market and exchange that simplifies participation free from short selling and the complex barriers often found in traditional markets. Listing on Upstream expands our global visibility and connects us with a broader investor community that shares our vision and long-term growth strategy.”

To view the full press release, visit https://ibn.fm/SqRi4

About KRTL Holding Group Inc.

KRTL Holding Group operates through its subsidiaries KRTL Biotech Inc. and KRTL International Corp. KRTL Biotech focuses on innovation in biotechnology, particularly in securing and developing global partnerships for the sourcing and distribution of critical active pharmaceutical ingredients (“APIs”) and wellness-focused compounds. KRTL International supports these efforts by managing regulatory compliance, trade logistics, and cross-border collaboration to ensure secure, FDA-compliant pathways into the U.S. market. With a strong commitment to quality, transparency, and sustainability, KRTL aims to position itself at the forefront of bio and agri-technological advancement.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

SOBRsafe (NASDAQ: SOBR) provider of next-generation transdermal alcohol detection solutions, will implement a 1-for-10 reverse stock split effective at 12:01 a.m. ET on April 4, 2025, following board approval and prior shareholder authorization. Post-split trading will begin the same day under the existing ticker with a new CUSIP number. The split will reduce outstanding shares from roughly 15.2 million to approximately 1.5 million, with all shareholders maintaining their proportional ownership. Fractional shares will be rounded up, and all related securities such as warrants and equity awards will be proportionally adjusted. Equiniti Trust Company, LLC will manage the exchange process.

To view the full press release, visit https://ibn.fm/ZOCrh

About SOBRsafe(TM)

Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a robust development pipeline, announced that CEO Seth Lederman, M.D., will present at the 2025 Jones Trading Healthcare and Innovation Conference. The presentation is scheduled for Wednesday, April 9, at 10 a.m. PT in Las Vegas.

To view the full press release, visit https://ibn.fm/sOHOo

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. The discussion will also detail Appili’s $33.2 million in non-dilutive funding, $117 million in new applications, and updates to its U.S. Air Force Academy agreement supporting ATI-1701, a biodefense vaccine candidate.

To view the full press release, visit https://ibn.fm/3L3Il

About Aditxt Inc.

Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Capstone Holding Corp. (NASDAQ: CAPS), a national building products distribution company that has successfully grown its business organically and through well-timed acquisitions, reported over 8% year-over-year revenue growth for its primary operating subsidiary, Instone, in the fourth quarter of 2024, as the company sets its sights on reaching a $100 million revenue run rate and at least $10 million in adjusted EBITDA by the end of 2025. CEO Matt Lipman emphasized the company’s commitment to doubling the business through strategic acquisitions, supported by favorable deal structures and multiple tuck-in and sister company opportunities under review. Operational highlights include the launch of Toro Stone across six states, strengthened gross margins through cost reductions, and continued national expansion in the building products sector. 

To view the full press release, visit https://ibn.fm/2ycdx 

About Capstone Holding Corp. 

Capstone Holding Corp. is a building products distribution company that has successfully grown its business organically and through well-timed acquisitions. The company intends to use the distribution backbone of its operating subsidiary, which currently services 31 U.S. states, to provide a value-added platform to make acquisitions. A key differentiator of the company’s strategy is that it maintains over half of its revenue from brands it owns or controls. Current products include stone veneer, landscape stone, and modular masonry fireplaces. Capstone’s corporate headquarters is located in Alsip, Illinois. For more information, visit the company’s website at www.CapstoneHoldingCorp.com 

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Thumzup (NASDAQ: TZUP), a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported a 243% compound annual growth rate, fueled by strategic expansion into South Florida, Miami, and Greater Salt Lake City. Thumzup’s platform integrates with major social networks, including Instagram Reels and X, reaching over 535 million users monthly.

To view the full press release, visit https://ibn.fm/v8bFY

About Thumzup®

Thumzup Media Corporation is democratizing the multi-billion dollar social media branding and marketing industry. Its flagship product, the Thumzup platform, utilizes a robust programmatic advertiser dashboard coupled with a consumer-facing App to enable individuals to get paid cash for posting about participating advertisers on major social media outlets through the Thumzup App. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through PayPal and other digital payment systems.

Thumzup was featured on CBS Los Angeles and in KTLA.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026.

To view the full press release, visit https://ibn.fm/NoBcQ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1×1 investor meetings. A webcast of the presentation will be available via the events section of Clene’s website.

To view the full press release, visit https://ibn.fm/rK99F

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

The MoneyShow Masters Symposium will be held in Dallas from April 4 to 5, 2025, and it will be an exclusive event that brings together high-net-worth investors and top experts in the field of finance. This two-day symposium will provide a robust platform for investors to learn from world-renowned fundamental and technical analysts, professional traders, and global market strategists.

MoneyShow has been working with traders and investors for the last 44 years, guiding and providing them with optimal resources to maximize their profits. MoneyShow hosts networking events where…

Read More>>

To learn more, please visit https://ibn.fm/XTsOD.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi’s clinical and preclinical cancer therapy programs.

To view the full press release, visit: https://ibn.fm/mvx3d

About Calidi Biotherapeutics

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, please visit www.calidibio.com

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Wheaton Precious Metals (NYSE: WPM) (TSX: WPM) filed its Form 40-F with the SEC, including audited financial statements for 2024, now available via EDGAR and the company’s website. The company also announced it will host its Annual and Special Meeting of Shareholders on May 9, 2025, at 10:30 a.m. PT. Shareholders may attend in person at Wheaton’s Vancouver office or virtually via the provided TSX Trust platform. Registered shareholders and proxyholders will be able to vote and participate online using their control numbers and the password “wheaton2025.”

To view the full press release, visit https://ibn.fm/skWTT

About Wheaton Precious Metals Corp.

Wheaton Precious Metals is the world’s premier precious metals streaming company with the highest-quality portfolio of long-life, low-cost assets. Its business model offers investors leverage to commodity prices and exploration upside but with a much lower risk profile than a traditional mining company. Wheaton delivers amongst the highest cash operating margins in the mining industry, allowing it to pay a competitive dividend and continue to grow through accretive acquisitions.

NOTE TO INVESTORS: The latest news and updates relating to WPM are available in the company’s newsroom at https://ibn.fm/WPM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company advancing innovative biotech assets, announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will assess [18F]3F4AP PET scans as a biomarker for demyelination, complementing MRI scans in both progressive and relapsing-remitting MS. The technique may enhance diagnostics in trials involving remyelinating and neuroprotective drugs, including Quantum’s Lucid-MS, which has shown promise in preserving the myelin sheath in preclinical models.

To view the full press release, visit https://ibn.fm/IQlIn

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company advancing innovative therapies, announced the launch of TONIX ONE™, a fully integrated digital platform designed to streamline migraine care. Built through partnerships with UpScript Telemedicine, ProModRx, Blink Health, and a leading symptom-tracking app, TONIX ONE connects patients with migraine specialists, facilitates e-prescriptions, and accelerates treatment access. The platform offers educational tools and real-time support to help patients overcome treatment barriers and improve care outcomes.

To view the full press release, visit https://ibn.fm/voAlr

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Brera Holdings (NASDAQ: BREA), an Ireland-based company advancing a multi-club ownership model in global football, celebrated the legacy of Advisory Board member and former Italy international Giuseppe Rossi during Fiorentina’s Pepito Day on March 22 in Florence. The tribute at Stadio Artemio Franchi featured tributes from fans, football legends, and Rossi’s former coaches, recognizing his career-defining moments and contributions to the sport. Brera’s executive team and investors attended both the match and a gala in Rossi’s honor, reflecting his ongoing influence on the company’s community-first strategy.

To view the full press release, visit https://ibn.fm/YVfx0

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

The 5th PRC Performance Optimization Summit by DGE will be held in Philadelphia on April 29-30, 2025. DGE invites industry professionals to discuss compliance and the expertise needed to get the best regulatory results for advertising/promotional material.

The summit is hosted by Dynamic Global Events (“DGE”), a pioneer in organizing B2B events for life science companies. DGE offers the biopharma, healthcare, and medical device industries a robust…

Read More>>

To learn more, please visit https://ibn.fm/3cdhG.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

MoneyShow, a leading producer of live and online financial conferences for investors, traders, and financial advisors, has announced the upcoming “Income, Growth, and Value Virtual Expo,” which is slated to take place on Apr. 29-30, 2025. “Markets have experienced increased volatility due to the announcement of sweeping tariffs, retaliatory measures from trading partners, stubborn inflation metrics, and more. However, the tumult in the markets and risk-off sentiment also presents unique and new opportunities for investors to earn higher yields and robust potential returns,” said MoneyShow’s Editor-in-Chief Mike Larson. “Our lineup of speakers includes veteran investors, highly successful traders, and renowned financial experts. They will share up-to-date insights to help attendees optimize their portfolios for growth – and protect against macroeconomic headwinds throughout 2025.”

To view the full press release, visit https://ibn.fm/oFyMd

About MoneyShow

MoneyShow has a long history of creating successful investors and traders through timely investing and trading education, delivered by powerful experts who are best-selling authors, market analysts, portfolio managers, award-winning financial journalists, and newsletter editors. With MoneyShow’s interactive environment, its audience of over one million passionate investors and traders are offered a unique format of live, interactive exchange, which generates unparalleled experience for both the expert and the investor and trader. With constant network expansion, MoneyShow continues to create broader distribution of its expert commentary through virtual events, face-to-face forums, social media, and in-depth courses that educate and guide qualified investors and traders to outperform the market. Each session energizes, empowers and educates everyone who participates. The opportunity for learning and profit within this highly charged atmosphere draws hundreds of thousands of enthusiasts, year after year.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

• The private credit sector is seeing remarkable growth with projections indicating that the market could surpass $1.5 trillion this year
• FAVO Capital has carved a niche for itself by recognizing the immense potential of alternative lending markets and private credit solutions
• The company’s approach to balancing risk and reward is built on a foundation of diversification and innovation

The financial landscape is rapidly evolving, with private credit and alternative lending markets emerging as key drivers of growth and innovation. As traditional banking institutions tighten their lending criteria and businesses seek more flexible financing solutions, the demand for alternative lending options, such as FAVO Capital (OTC: FAVO), continues to soar.

This shift is fueling remarkable growth in the private credit sector, with projections indicating that the market could surpass $1.5 trillion this year (https://ibn.fm/wTPRv). Alternative lending platforms, peer-to-peer financing and direct lending solutions are becoming increasingly attractive to both borrowers and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

GivBux (OTC: GBUX), a publicly traded Super App and charitable giving platform, announced plans to sell a 30% equity stake for $212 million through a non-dilutive transaction aimed at preserving shareholder value. Proceeds will be invested in an income-focused strategy led by a private credit asset manager specializing in real estate, with the goal of generating steady cash flow to fuel the company’s platform expansion. The majority shareholder has agreed to retire a portion of shares to further reduce potential dilution.

To view the full press release, visit https://ibn.fm/R5IhG

About GivBux Inc.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly and easily at more than 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to “give back.” The GivBux Super App is free to use and available now. The GivBux Super App is constantly evolving and adding new enhancements and functionalities, including social networking, e-commerce, banking, messaging, food delivery and transportation. GivBux is forging a new path in e-commerce and charitable giving and aspires to build the largest community of givers, initially in the United States and eventually worldwide. To learn more about the company, visit www.GivBux.com.

NOTE TO INVESTORS: The latest news and updates relating to GBUX are available in the company’s newsroom at https://ibn.fm/GBUX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

As venture debt enters a pivotal phase in 2025, investors are faced with a more complex and volatile lending environment. The shifting dynamics, influenced by rising interest rates and the unprecedented collapse of Silicon Valley Bank, demand a much more sophisticated approach to risk management. While venture debt continues to serve as an essential source of capital for startups, understanding the intricate challenges of the current landscape is crucial for navigating this evolving market.

Evolving Risk Landscape: Mitigating Uncertainty

The key to navigating venture debt in this era lies in rigorous due diligence. Investors must go beyond surface-level assessments of a company’s financials and consider a broader spectrum of factors that could influence its solvency. One of the most pressing concerns for lenders today is the stability of a startup’s…

Read More>>

More information about the event, including registration details, can be found at: Venture Debt Conference 2025.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company, announced the closing of its final tranche in a debenture unit offering, raising a total of CAD $5 million. Proceeds will support research and development, commercialization efforts, and working capital, with management stating the funding provides runway through the first quarter of 2027. The company also began developing a hospital-use formulation of rekvry™, its alcohol misuse treatment designed to alleviate healthcare system strain.

To view the full press release, visit https://ibn.fm/unRCH

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a Swiss-hosted cybersecurity and privacy communications platform, announced the closing of the final tranche of its non-brokered private placement, raising gross proceeds of CA$237,106. The offering included 6,973,705 units priced at CA$0.034, each consisting of one common share and one full warrant exercisable at CA$0.055 for 24 months. Company insiders, including the CEO, CFO and a board member, collectively purchased 2,050,000 units. Proceeds will be used to expand U.S. marketing efforts and support general corporate purposes.

To view the full press release, visit https://ibn.fm/5YbBI

About Sekur Private Data Ltd.

Sekur Private Data is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The company distributes a suite of encrypted emails, secure messengers and secure communication tools. It sells its products through its own website, approved distributors and telecommunication companies worldwide. Sekur Private Data serves consumers, businesses and governments worldwide. For more information, visit the company’s website at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

• SMBs face severe funding challenges, with over 75% of owners worried about securing credit amid rising interest rates and stricter lending practices
• FAVO Capital’s platform in development will enable businesses to apply for funding, track progress, and manage repayments, complemented by a mobile app for real-time insights and personalized recommendations
• FAVO Capital’s tailored financial products provide essential support for SMBs, enabling them to scale operations and contribute to economic stability

Access to capital has long been the lifeline of small and medium-sized businesses (“SMBs”), but today, that lifeline is fraying. Rising interest rates, stricter lending practices, and ongoing banking instability have turned what was once an accessible stream of funding into a nearly insurmountable challenge. The landscape has changed dramatically from just a few years ago when government stimulus programs and looser lending standards made capital readily available. Now, small business owners are facing one of the toughest financial climates in recent history, with significant implications for employment, salaries, and overall economic stability.

The Capital Crunch Facing SMBs

According to a 2023 survey conducted by Goldman Sachs’ 10,000 Small Businesses Voices initiative, more than 75% of small business owners are worried about their ability to secure credit. This marks a stark reversal from 2022, when 77% of respondents expressed confidence in their access to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, sees its work with Juve Stabia Academy in Naples as a prime example of how to foster the next generation of football talent
• In December 2024, the company signed an agreement to acquire a majority ownership stake in SS Juve Stabia srl, currently in playoff position in Italy’s Serie B league
• Juve Stabia has produced amazing talents such as Luigi Vitale, Raffaele Ametrano, Giovanni Cervone, and Antonio Donnarumma, three of whom have had over 130 Italian Serie A league appearances
• Brera looks to replicate this success through its active support of the Juve Stabia Academy, strengthening the pathways for emerging talent while also offering a way to explore opportunities to connect academies and football schools across different geographies

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, is committed to supporting grassroots football and expanding opportunities for young athletes, with the Juve Stabia Academy being a prime example. This initiative looks to tap into talent early, a tried-and-tested approach to creating new opportunities for youth players while also strengthening football communities in Italy and worldwide.

“Our commitment to Juve Stabia Academy aligns with our broader mission to empower young athletes and foster sustainable football ecosystems,” noted Daniel McClory, Brera Holdings’ Executive Chairman. “By supporting initiatives like this, we aim to create new opportunities for youth players while…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The discussion will emphasize how the CaSe Platform supports Pearsanta’s mission of advancing early detection and prevention in oncology. Featured participants include Dr. Shahrokh Shabahang of Aditxt, Chris Mitton of Pearsanta, and Dr. Roger Giese, the platform’s co-inventor.

To view the full press release, visit https://ibn.fm/KE1wL

About Aditxt Inc.

Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Knightscope (NASDAQ: KSCP), a developer of autonomous security robots and AI technologies, has entered into definitive agreements to sell 625,000 shares of common stock at $2.75 per share in a registered direct offering, expected to close on or about March 31, 2025. Gross proceeds are anticipated to total approximately $1.7 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent. Knightscope plans to use the net proceeds for working capital and general corporate purposes.

To view the full press release, visit https://ibn.fm/AnSBh

About Knightscope, Inc.

Knightscope builds cutting-edge technologies to improve public safety. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day period was approximately $37.9 million, while its stockholders’ equity as of Dec. 31, 2024, was $9.3 million—both below the $50 million threshold. Annovis will submit a compliance plan within 45 days and may remain listed during an 18-month cure period if the NYSE accepts the plan. Its stock will continue trading under the “ANVS” symbol with a “.BC” indicator reflecting noncompliance status.

To view the full press release, visit https://ibn.fm/CTSkW

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported strong fourth quarter and full-year 2024 results, highlighted by 40,147 ounces of gold production and net income of $47.6 million, or $0.21 per share, in its first full quarter of commercial output from the Tocantinzinho Mine. All-in sustaining costs for the quarter were $862 per ounce, with adjusted EBITDA of $77.9 million and free cash flow totaling $53 million. For the year, the company produced 63,566 ounces of gold, generating $62 million in net income and ending with $141.2 million in cash. GMIN also advanced its growth strategy with the acquisition of the Oko West project in Guyana and the Gurupi project in Brazil, positioning the company to exceed 500,000 ounces of annual gold production in the coming years.

To view the full press release, visit https://ibn.fm/VRl1r

About G Mining Ventures Corp.

G Mining Ventures Corp. is a mining company engaged in the acquisition, exploration and development of precious metal projects to capitalize on the value uplift from successful mine development. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored by the Tocantinzinho Gold Mine (” TZ “) in Brazil and Oko West Project in Guyana , both mining friendly and prospective jurisdictions.

NOTE TO INVESTORS: The latest news and updates relating to GMINF are available in the company’s newsroom at https://ibn.fm/GMINF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Newton Golf (NASDAQ: NWTG) has completed a strategic rebranding to emphasize its commitment to innovation and align more closely with its mission of integrating advanced physics principles into golf-equipment design. The restructuring was not merely a change in name but a reflection of Newton Golf’s dedication to creating equipment that leverages the laws of physics to benefit golfers of all skill levels. Central to the company’s product lineup are the Newton Gravity Putters and Newton Motion Shafts. Renowned for their ultra-low balance point (“ULBP”) technology, the gravity putters promote a smoother, more controlled putting stroke. The innovation has garnered attention on professional tours, with several PGA champions integrating these putters into their games. Further, the motion shafts are designed to optimize energy transfer and enhance swing consistency, embodying Newton Golf’s commitment to precision engineering.

To view the full article, visit https://ibn.fm/qfYLq

About Newton Golf Company

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, the company creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. Newton Golf’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant. The company secured approximately $10 million in gross proceeds from the offering. TransCode intends to use the proceeds primarily for product development activities, including one or more clinical trials with its lead therapeutic candidate, TTX-MC138, including related IND-enabling studies, as well as for working capital and other general corporate purposes. ThinkEquity acted as sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/Eab7z

About TransCode Therapeutics Inc.

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The agreement positions Scinai to advance treatments for high-mortality conditions like pemphigus and Stevens-Johnson Syndrome without immunosuppression, with Pincell’s leadership expected to integrate into Scinai’s expanding European operations.

To view the full press release, visit https://ibn.fm/F5KJ5

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Oragenics (NYSE American: OGEN) reported significant strategic progress in Q1 2025 as it advances ONP-002, its intranasal concussion therapy, toward clinical Phase IIa trials in Australia. The company secured a partnership with BRAINBox Solutions to integrate diagnostic biomarkers with its treatment platform and raised approximately $5 million through a mix of equity and non-dilutive debt. Oragenics also finalized regulatory submissions and drug production, with first patient enrollment expected in Q2. With no FDA-approved treatments for concussion, ONP-002 is positioned as a potential first-in-class therapy addressing a major unmet need.

To view the full press release, visit https://ibn.fm/BrTCE

About Oragenics

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT) has commenced its 2025 winter exploration program at the Hatchet Lake Uranium Project in Saskatchewan’s Athabasca Basin, aiming to drill 2,000 meters across eight holes targeting high-priority zones. The initiative builds on previous promising results from Denison Mines (NYSE American: DNN), Foremost’s largest shareholder, and focuses on uranium mineralization along key conductive trends. As uranium demand surges amid a global energy transition and supply shortfalls, Foremost is positioning itself to capitalize on the market’s growing need for new sources in stable jurisdictions.

To view the full press release, visit https://ibn.fm/cgh8o

About Foremost Clean Energy Ltd.

Foremost Clean Energy, assuming the effectiveness of the transaction, will be an emerging North American uranium exploration company with interests in 10 prospective properties spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin. As global demand for decarbonization accelerates, the need for nuclear power is crucial. Foremost expects to be positioned to capitalize on the growing demand for uranium through discovery in a top jurisdiction with the objective to support the world’s energy-transition goals. Alongside its exploration partner Denison, Foremost will be committed to a strategic and disciplined exploration strategy to identify resources by testing drill–ready targets with identified mineralization along strike of recent major discoveries. Foremost also maintains a secondary portfolio of significant lithium projects at different stages of development spanning over 50,000 acres across Manitoba and Quebec. For more information about the company, visit www.ForemostCleanEnergy.com.  

NOTE TO INVESTORS: The latest news and updates relating to FMST are available in the company’s newsroom at http://ibn.fm/FMST

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Nightfood Holdings (OTCQB: NGTF) announced it is nearing the completion of two key acquisitions—Carryout Supplies (S W C Group) and Skytech Automated Solutions—as part of its strategy to lead innovation at the intersection of AI, robotics and hospitality. The acquisition of Carryout Supplies is expected to close imminently, followed closely by the acquisition of Skytech, which recently expanded its AI-powered Laundry Helper robot to a second location. These moves mark a significant milestone in Nightfood’s evolution from a specialty food company to a hospitality tech innovator, with further strategic expansion under active consideration.

To view the full press release, visit https://ibn.fm/uBclo

About Nightfood Holdings Inc.

Nightfood is a forward-thinking holding company dedicated to identifying and capitalizing on explosive market trends within the hospitality, food services, consumer packaged goods and commercial real estate sectors. The company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth by leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval. Nightfood is at the forefront of introducing and deploying artificial intelligence-enabled robotics products, revolutionizing operational efficiencies and customer experiences across the company’s focus areas. Additionally, the company is committed to developing and marketing wellness-focused consumer packaged goods, meeting the growing demand for healthier and functional options. Through these strategic initiatives, Nightfood endeavors to drive significant value and growth for its stakeholders. For more information, visit the company’s website at www.NightFood.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Quantum BioPharma (NASDAQ: QNTM) has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor. Lynch, a prominent advocate against micro-cap stock manipulation and CEO of Power Nickel (TSXV: PNPN), brings deep experience in biotech, mining finance and market reform. He is also a co-founder of Cardiol Therapeutics (NASDAQ: CRDL) and a consultant to bionxt solutions. As part of the appointment, Quantum granted Lynch 50,000 stock options at C$9.90 per share, expiring March 26, 2027.

To view the full press release, visit https://ibn.fm/47G6M

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN